SCHEMBL16106500

SCHEMBL16106500

OCCCCCCCCCCCc1ccc2c(Cl)ccc(O)c2n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
BRD4 O60885 1/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MAPT P10636 1/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
PIM1 P11309 1/20 0.40
OPRK1 P41145 1/20 0.35
KMT2A Q03164 1/20 0.35
IGF1R P08069 1/20 0.33
ALOX15 P16050 1/20 0.33
TLR8 Q9NR97 1/20 0.31
NQO2 P16083 1/20 0.30
KCNH2 Q12809 1/20 0.30
DHFR P00374 1/20 0.30
CCR1 P32246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393540 0.86 MAPT (0.49) KDM4EBRD4LMNAHSP90AA1MAPT
SCHEMBL16106633 0.84 OPRK1 (0.54) KDM4ELMNAMAPTOPRK1KMT2A
SCHEMBL16106459 0.81 MAPT (0.51) KDM4ELMNAHSP90AA1MAPTOPRK1
SCHEMBL28250159 0.81 CCR1 (0.48) KDM4EBRD4LMNAHSP90AA1MAPT
SCHEMBL16106430 0.81 PDE4B (0.42) KDM4ENQO2
SCHEMBL16106477 0.81 PDE4B (0.42) KDM4ENQO2
SCHEMBL16106657 0.81 PDE4B (0.42) KDM4ENQO2
SCHEMBL16106428 0.81 PDE4B (0.42) KDM4ENQO2
SCHEMBL16106568 0.81 PDE4B (0.42) KDM4ENQO2
SCHEMBL16106630 0.81 PDE4B (0.42) KDM4ENQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9302992-B2 Multifunctional quinoline derivatives as anti-neurodegenerative agents Annji Pharmaceutical Co., Ltd. (TW) 2016-04-05 US claimed
US-20140296251-A1 MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS Annji Pharmaceutical Co., Ltd. (TW) 2014-10-02 US claimed
US-9302992-B2 Multifunctional quinoline derivatives as anti-neurodegenerative agents Annji Pharmaceutical Co., Ltd. (TW) 2016-04-05 US disclosed
US-9302992-B2 Multifunctional quinoline derivatives as anti-neurodegenerative agents Annji Pharmaceutical Co., Ltd. (TW) 2016-04-05 US disclosed
US-9302992-B2 Multifunctional quinoline derivatives as anti-neurodegenerative agents Annji Pharmaceutical Co., Ltd. (TW) 2016-04-05 US disclosed
US-20140296251-A1 MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS Annji Pharmaceutical Co., Ltd. (TW) 2014-10-02 US disclosed
US-20140296251-A1 MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS Annji Pharmaceutical Co., Ltd. (TW) 2014-10-02 US disclosed
US-20140296251-A1 MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS Annji Pharmaceutical Co., Ltd. (TW) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296251-A1 MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS NLN, SNCA, CLN6 KDM4E 3330/4885BRD4 496/4885LMNA 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.